Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

See the follow up and data collection page for details of adverse event reporting.

Suspected Unexpected Serious Adverse Reactions (SUSAR)

SUSAR Q1 2023 – none reported

SUSAR Q4 2022 – none reported

SUSAR Q3 2022 – none reported

SUSAR Q2 2022 – none reported

SUSAR Q1 2022 – none reported 

SUSAR Q4 2021

SUSAR Q3 2021

SUSAR Q2 2021

SUSAR Q1 2021

SUSAR Q4 2020

SUSAR Q3 2020

SUSAR Q1-2 2020

Annual Reports

Annual Progress Report to Research Ethics Committtee 2022

Development Safety Update Report DSUR 2022

Annual Progress Report to Research Ethics Committee 2021

Development Safety Update Report (DSUR) 2021